After closing two mega-rounds of investment within eight months of each other, a booming Rubius Therapeutics has just set terms for a $200 million IPO.
The Cambridge, Massachusetts-based company plans to command a $1.8 billion market cap, offering 9.53 million shares between $20 to $22 each. Rubius will list on the Nasdaq under the ticker $RUBY.
The IPO news comes days after the company announced a new $155 million project to renovate a 135,000 square-foot manufacturing site in Rhode Island for its cell therapies. Developing a new class of medicine calls for a hefty manufacturing capacity.
Rubius’ idea is to take red blood cells — designed by nature to transport oxygen — and hijack them through genetic engineering tech to get them to carry proteins needed to fight various diseases. It’s an off-the-shelf approach, rather than one personalized for each patient.
And it’s a platform play — a particular favorite of Flagship Pioneering, the startup factory that churned out Rubius.
Rubius’ platform has already attracted big financial support, raising $220 million in two round since last summer.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,100+ biopharma pros who read Endpoints News by email every day.Free Subscription